{"protocolSection":{"identificationModule":{"nctId":"NCT00113516","orgStudyIdInfo":{"id":"A6181057"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer","officialTitle":"Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2010-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-09"},"primaryCompletionDateStruct":{"date":"2009-03","type":"ACTUAL"},"completionDateStruct":{"date":"2009-03","type":"ACTUAL"},"studyFirstSubmitDate":"2005-06-08","studyFirstSubmitQcDate":"2005-06-08","studyFirstPostDateStruct":{"date":"2005-06-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-03-08","resultsFirstSubmitQcDate":"2010-04-02","resultsFirstPostDateStruct":{"date":"2010-05-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-05-14","lastUpdatePostDateStruct":{"date":"2010-05-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Director, Clinical Trial Disclosure Group","oldOrganization":"Pfizer Inc"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Lung Neoplasms"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":84,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: carboplatin","Drug: paclitaxel","Drug: sunitinib"]}],"interventions":[{"type":"DRUG","name":"carboplatin","description":"AUC of 6 mg\\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.","armGroupLabels":["1"],"otherNames":["Paraplatin"]},{"type":"DRUG","name":"paclitaxel","description":"175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.","armGroupLabels":["1"],"otherNames":["Taxol"]},{"type":"DRUG","name":"sunitinib","description":"50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).","armGroupLabels":["1"],"otherNames":["SUTENT, SU011248"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of Subjects Surviving at One Year","description":"Proportion of those surviving at the end of one year from the first dose of study treatment. In the absence of confirmation of death, survival time was censored at the last date the subject was known to be alive. Patients lacking data beyond the day of first dose had their survival time censored at Day 1 of treatment.","timeFrame":"From start of treatment until 1 year or death"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"PFS was defined as the time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date - first paclitaxel/carboplatin dose date +1)/7.02.","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib) or death"},{"measure":"Time to Tumor Progression (TTP)","description":"TTP was defined as the time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date - first paclitaxel/carboplatin dose date +1)/7.02.","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib)"},{"measure":"Duration of Response (DR)","description":"DR=time from the first documentation of objective tumor response (complete response \\[CR\\] or partial response \\[PR\\]) that was subsequently confirmed to first documentation of objective disease progression or death due to any cause, whichever was first. CR=disappearance of all target lesions. PR=a \\> = 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. If tumor progression data included more than 1 date, first date was used. DR (in weeks) was calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/7.02.","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib) or death"},{"measure":"Number of Subjects With Overall Confirmed Objective Disease Response","description":"Objective disease response = subjects with confirmed CR or PR according to the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.0). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib)"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death - date of paclitaxel/carboplatin first dose +1)/30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of paclitaxel/carboplatin had their survival time censored at Day 1 of paclitaxel/carboplatin treatment.","timeFrame":"From start of study treatment until death"},{"measure":"Trough Plasma Concentration (Ctrough) of Sunitinib","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Ctrough of SU-012662 (Sunitinib's Metabolite)","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Ctrough of Total Drug (Sunitinib + SU-012662)","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Dose-Corrected Ctrough of Sunitinib","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Dose-Corrected Ctrough of SU-012662 (Sunitinib's Metabolite)","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662)","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2"},{"measure":"Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Concentration at Baseline","description":"Concentration of VEGFR3 at baseline.","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"VEGFR3 Ratio to Baseline at Each Time Point","description":"VEGFR3 concentration at each time point divided by VEGFR3 concentration at baseline (ratio to baseline).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"VEGF-C Concentration at Baseline","description":"Concentration of VEGF-C at baseline.","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"VEGF-C Ratio to Baseline at Each Time Point","description":"VEGF-C concentration at each time point divided by VEGF-C concentration at baseline (ratio to baseline).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Soluble E-Selectin at Baseline","description":"Concentration of soluble E-Selectin at baseline.","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"Soluble E-Selectin Ratio to Baseline at Each Time Point","description":"Soluble E-Selectin concentration at each time point divided by soluble E-Selectin concentration at baseline (ratio to baseline).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2"},{"measure":"VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of VEGFR3 at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median VEGFR3 concentration at each time point divided by median VEGFR3 concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of VEGF-C at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median VEGF-C concentration at each time point divided by median VEGF-C concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of soluble E-selectin at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2"},{"measure":"Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median soluble E-selectin concentration at each time point divided by median soluble E-selectin concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1)divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after Stratification by \\< or \\> = median changes from Baseline in VEGFR3 at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","timeFrame":"[Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after stratification by \\< or \\> = median changes from baseline in VEGFR3 at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline","description":"OS = time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death minus date of sunitinib first dose +1)divided by 30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGFR3 at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"OS = time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death minus date of sunitinib first dose +1) divided by 30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline","description":"OS=time from start of study treatment to death due to any cause. OS (in months) calculated as (date of death minus date of sunitinib first dose +1) divided by 30.4. For subjects not expiring their survival times were censored at last date of known contact they were known to be alive. Subjects lacking data beyond day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2"},{"measure":"Immunohistochemical Staining of Paraffin Embedded Tumor Tissue","description":"Previously collected tumor paraffin block (or 12-20 10-micron slides prepared for the paraffin block) for correlative laboratory analysis.","timeFrame":"Screening"},{"measure":"Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms to Safety of Sunitinib","description":"A blood sample (6 mL) was collected and used to isolate DNA. These samples were not anonymized.","timeFrame":"Within 7 days of Day 1"},{"measure":"Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)","description":"EORTC QLQ-C30 scales: global health/QoL, functional domains (physical, role, cognitive, emotional, social), and symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea). Recall period: past week; response range: not at all to very much, global/QOL range: very poor to excellent. Scale score range: 0 to 100. Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms. Change: score at each visit in Part 2 minus baseline score in Part 1.","timeFrame":"Baseline (Part 1) to Cycle1 (Days 1 [baseline], 28), Cycles 2 and 3 (Days 1, 28), and Cycle 4 (Day 1) in Part 2"},{"measure":"Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13)","description":"QLQ-LC13 assessed lung cancer symptoms (dyspnea, coughing, dysphasia, hemoptysis, sore mouth, peripheral neuropathy, alopecia, chest pain, arm pain, shoulder pain, and pain in other parts). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms. Change: score at each visit in Part 2 minus baseline score in Part 1.","timeFrame":"Baseline (Part 1) to Cycle1 (Days 1 [baseline], 28), Cycles 2 and 3 (Days 1, 28), and Cycle 4 (Day 1) in Part 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven NSCLC\n* Stage IIIB (locally advanced with malignant effusion) or Stage IV disease\n* No prior therapy for NSCLC\n* Evidence of unidimensionally measurable disease\n\nExclusion Criteria:\n\n* Previous treatment with systemic chemotherapy for lung cancer\n* History of or known brain metastases\n* NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment\n* Evidence of hemoptysis within 4 weeks of starting study treatment\n* Serious acute or chronic illness or recent history of significant cardiac abnormality\n* Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Pfizer Investigational Site","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Pfizer Investigational Site","city":"Newark","state":"Delaware","zip":"19718","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Pfizer Investigational Site","city":"Wilmington","state":"Delaware","zip":"19899","country":"United States","geoPoint":{"lat":39.74595,"lon":-75.54659}},{"facility":"Pfizer Investigational Site","city":"Maywood","state":"Illinois","zip":"60153","country":"United States","geoPoint":{"lat":41.8792,"lon":-87.84312}},{"facility":"Pfizer Investigational Site","city":"Jeffersonville","state":"Indiana","zip":"47130","country":"United States","geoPoint":{"lat":38.27757,"lon":-85.73718}},{"facility":"Pfizer Investigational Site","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Pfizer Investigational Site","city":"Louisville","state":"Kentucky","zip":"40217","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Pfizer Investigational Site","city":"Louisville","state":"Kentucky","zip":"40241","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Pfizer Investigational Site","city":"Shelbyville","state":"Kentucky","zip":"40065","country":"United States","geoPoint":{"lat":38.21201,"lon":-85.22357}},{"facility":"Pfizer Investigational Site","city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}},{"facility":"Pfizer Investigational Site","city":"Franklin","state":"Tennessee","zip":"37067","country":"United States","geoPoint":{"lat":35.92506,"lon":-86.86889}},{"facility":"Pfizer Investigational Site","city":"Gallatin","state":"Tennessee","zip":"37066","country":"United States","geoPoint":{"lat":36.38838,"lon":-86.44666}},{"facility":"Pfizer Investigational Site","city":"Hermitage","state":"Tennessee","zip":"37076","country":"United States","geoPoint":{"lat":36.19617,"lon":-86.6225}},{"facility":"Pfizer Investigational Site","city":"Lebanon","state":"Tennessee","zip":"37087","country":"United States","geoPoint":{"lat":36.20811,"lon":-86.2911}},{"facility":"Pfizer Investigational Site","city":"Murfreesboro","state":"Tennessee","zip":"37130","country":"United States","geoPoint":{"lat":35.84562,"lon":-86.39027}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37203-1632","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37205","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37207","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37211","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Smyrna","state":"Tennessee","zip":"37167","country":"United States","geoPoint":{"lat":35.98284,"lon":-86.5186}},{"facility":"Pfizer Investigational Site","city":"Burleson","state":"Texas","zip":"76028","country":"United States","geoPoint":{"lat":32.54208,"lon":-97.32085}},{"facility":"Pfizer Investigational Site","city":"Cleburne","state":"Texas","zip":"76031","country":"United States","geoPoint":{"lat":32.34764,"lon":-97.38668}},{"facility":"Pfizer Investigational Site","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Pfizer Investigational Site","city":"Mineral Wells","state":"Texas","zip":"76067","country":"United States","geoPoint":{"lat":32.80846,"lon":-98.11282}},{"facility":"Pfizer Investigational Site","city":"Weatherford","state":"Texas","zip":"76086","country":"United States","geoPoint":{"lat":32.7593,"lon":-97.79725}},{"facility":"Pfizer Investigational Site","city":"Vancouver","state":"British Columbia","zip":"V5Z4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Pfizer Investigational Site","city":"Montreal","state":"Quebec","zip":"H2L 4M1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Pfizer Investigational Site","city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Pfizer Investigational Site","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181057&StudyName=A%20Study%20Of%20SU011248%20As%20Therapy%20In%20Patients%20With%20Locally%20Advanced%20Or%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"During Part 1, subjects received carboplatin plus paclitaxel 172-225 mg/m2. Those same subjects were eligible for continuation in Part 2 where they received sunitinib 50 mg. 66 subjects continued in Part 2.","groups":[{"id":"FG000","title":"Carboplatin Plus Paclitaxel","description":"Carboplatin Plus Paclitaxel 172-225 mg/m2"},{"id":"FG001","title":"Sunitinib","description":"Sunitinib 50 mg"}],"periods":[{"title":"Part 1","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"66 subjects continued into Part 2 of the study.","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Did Not Meet Entrance Criteria","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Laboratory Abnormality","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Missing","reasons":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"0"}]}]},{"title":"Part 2","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"66"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"66"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"37"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Laboratory Abnormality","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"84"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"< 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}]},{"title":"> = 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"31"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"53"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Surviving at One Year","description":"Proportion of those surviving at the end of one year from the first dose of study treatment. In the absence of confirmation of death, survival time was censored at the last date the subject was known to be alive. Patients lacking data beyond the day of first dose had their survival time censored at Day 1 of treatment.","populationDescription":"Intent-to-treat (ITT) population = all subjects enrolled in the study who received at least 1 dose of paclitaxel/carboplatin.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"proportion","timeFrame":"From start of treatment until 1 year or death","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.405"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"The study was designed to test the null hypothesis that the true one-year probability of survival is 0.40 versus the alternative hypothesis that the true one-year probability of survival is at least 0.55. The sample size was determined using a One-Sample Survival design, assuming alpha=0.05 (1-sided), power= 0.90, 6 month accrual, a minimum follow-up period of 12 months, and an expectation that approximately 5% of subjects may be lost to follow-up.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Kaplan-Meier","paramType":"probability","paramValue":"0.405","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.315","ciUpperLimit":"0.494","estimateComment":"The probability of survival along with the corresponding confidence interval (CI) (for the log \\[-log (1-year survival rate)\\]) was calculated using a normal approximation and then back transformed to give a CI for the 1-year survival rate itself."}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"PFS was defined as the time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date - first paclitaxel/carboplatin dose date +1)/7.02.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib) or death","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"21.4","upperLimit":"28.2"}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP)","description":"TTP was defined as the time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date - first paclitaxel/carboplatin dose date +1)/7.02.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib)","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","lowerLimit":"22.6","upperLimit":"29.3"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR)","description":"DR=time from the first documentation of objective tumor response (complete response \\[CR\\] or partial response \\[PR\\]) that was subsequently confirmed to first documentation of objective disease progression or death due to any cause, whichever was first. CR=disappearance of all target lesions. PR=a \\> = 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. If tumor progression data included more than 1 date, first date was used. DR (in weeks) was calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/7.02.","populationDescription":"ITT. DR was calculated for the subgroup of subjects with objective response. 23 subjects reported CR or PR response and were analyzed for DR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib) or death","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"16.3","upperLimit":"40.1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Overall Confirmed Objective Disease Response","description":"Objective disease response = subjects with confirmed CR or PR according to the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.0). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From start of treatment until Day 21 of Cycles 2 and 4 (Carboplatin plus Paclitaxel), Day 28 of Cycles 1, 2, 3, 4, and even cycles thereafter (Sunitinib)","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Objective Response Rate (ORR) (percent)","paramValue":"27.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"18.2","ciUpperLimit":"38.2"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death - date of paclitaxel/carboplatin first dose +1)/30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of paclitaxel/carboplatin had their survival time censored at Day 1 of paclitaxel/carboplatin treatment.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From start of study treatment until death","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"8.1","upperLimit":"12.2"}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentration (Ctrough) of Sunitinib","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","populationDescription":"Pharmacokinetic (PK) = all subjects enrolled in the study who received at least 1 dose of carboplatin/paclitaxel or sunitinib. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms (ng)/milliliter (mL)","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=51)","categories":[{"measurements":[{"groupId":"OG000","value":"57.69","spread":"29.37"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"50.88","spread":"33.67"}]}]},{"title":"Cycle 3, Day 28 (n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"41.55","spread":"24.28"}]}]},{"title":"Cycle 5, Day 28 (n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"38.57","spread":"21.83"}]}]}]},{"type":"SECONDARY","title":"Ctrough of SU-012662 (Sunitinib's Metabolite)","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","populationDescription":"PK. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=51)","categories":[{"measurements":[{"groupId":"OG000","value":"27.54","spread":"15.10"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"23.47","spread":"20.99"}]}]},{"title":"Cycle 3, Day 28 (n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"18.37","spread":"9.05"}]}]},{"title":"Cycle 5, Day 28 (n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"15.67","spread":"7.12"}]}]}]},{"type":"SECONDARY","title":"Ctrough of Total Drug (Sunitinib + SU-012662)","description":"Ctrough = the plasma concentration prior to study drug administration. On Day 28, this parameter provided and idea of the concentration at steady state since no big fluctuation was expected in a 24 hour interval.","populationDescription":"PK. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=51)","categories":[{"measurements":[{"groupId":"OG000","value":"85.23","spread":"42.22"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"74.35","spread":"51.60"}]}]},{"title":"Cycle 3, Day 28 (n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"59.92","spread":"30.72"}]}]},{"title":"Cycle 5, Day 28 (n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"54.24","spread":"27.90"}]}]}]},{"type":"SECONDARY","title":"Dose-Corrected Ctrough of Sunitinib","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","populationDescription":"PK. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"64.10","spread":"26.84"}]}]},{"title":"Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"59.85","spread":"40.45"}]}]},{"title":"Cycle 3, Day 28 (n=13)","categories":[{"measurements":[{"groupId":"OG000","value":"49.59","spread":"21.86"}]}]},{"title":"Cycle 5, Day 28 (n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"54.51","spread":"13.67"}]}]}]},{"type":"SECONDARY","title":"Dose-Corrected Ctrough of SU-012662 (Sunitinib's Metabolite)","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","populationDescription":"PK. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"27.90","spread":"14.66"}]}]},{"title":"Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"27.37","spread":"30.55"}]}]},{"title":"Cycle 3, Day 28 (n=13)","categories":[{"measurements":[{"groupId":"OG000","value":"20.64","spread":"9.97"}]}]},{"title":"Cycle 5, Day 28 (n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"22.29","spread":"8.35"}]}]}]},{"type":"SECONDARY","title":"Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662)","description":"Ctrough = the plasma concentration prior to study drug administration. Dose correction was made to the initial intended dose in Cycle 1. This was determined due to potential dose changes throughout the study in different subjects. It was calculated as the observed values multiplied by the reference dose (50 mg) divided by the actual dose. For dose-corrected trough concentration, only trough concentration values from subjects who received sunitinib during at least the last 10 consecutive days of dosing at the same dose level were included.","populationDescription":"PK. Subjects with plasma values below limit of quantification were excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"predose on Day 28 of Cycles 1, 2, 3, and 5 of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"92.00","spread":"40.31"}]}]},{"title":"Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"87.22","spread":"68.28"}]}]},{"title":"Cycle 3, Day 28 (n=13)","categories":[{"measurements":[{"groupId":"OG000","value":"70.24","spread":"28.71"}]}]},{"title":"Cycle 5, Day 28 (n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.80","spread":"20.13"}]}]}]},{"type":"SECONDARY","title":"Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Concentration at Baseline","description":"Concentration of VEGFR3 at baseline.","populationDescription":"Modified ITT population (MITT) = all subjects enrolled in the study who received at least 1 dose of paclitaxel/carboplatin and at least 1 dose of Sunitinib.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"picograms (pg)/milliliter (mL)","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30382.83","spread":"19134.12"}]}]}]},{"type":"SECONDARY","title":"VEGFR3 Ratio to Baseline at Each Time Point","description":"VEGFR3 concentration at each time point divided by VEGFR3 concentration at baseline (ratio to baseline).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers at baseline and at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=46)","categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.201"}]}]},{"title":"Cycle 2, Day 1 (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.255"}]}]},{"title":"Cycle 2, Day 28 (n=29)","categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.165"}]}]},{"title":"Cycle 3, Day 1 (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.288"}]}]},{"title":"Cycle 3, Day 28 (n=12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.111"}]}]},{"title":"Cycle 5, Day 28 (n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.163"}]}]}]},{"type":"SECONDARY","title":"VEGF-C Concentration at Baseline","description":"Concentration of VEGF-C at baseline.","populationDescription":"MITT. Number of participants analyzed = number of subjects with VEGF-C data at Baseline.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"793.19","spread":"323.770"}]}]}]},{"type":"SECONDARY","title":"VEGF-C Ratio to Baseline at Each Time Point","description":"VEGF-C concentration at each time point divided by VEGF-C concentration at baseline (ratio to baseline).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers at baseline and at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=46)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.342"}]}]},{"title":"Cycle 2, Day 1 (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"0.396"}]}]},{"title":"Cycle 2, Day 28 (n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.577"}]}]},{"title":"Cycle 3, Day 1 (n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.460"}]}]},{"title":"Cycle 3, Day 28 (n=12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.340"}]}]},{"title":"Cycle 5, Day 28 (n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.269"}]}]}]},{"type":"SECONDARY","title":"Soluble E-Selectin at Baseline","description":"Concentration of soluble E-Selectin at baseline.","populationDescription":"MITT. Number of participants analyzed = number of subjects with soluble E-Selectin data at Baseline.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms (ng)/mL","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.06","spread":"11.474"}]}]}]},{"type":"SECONDARY","title":"Soluble E-Selectin Ratio to Baseline at Each Time Point","description":"Soluble E-Selectin concentration at each time point divided by soluble E-Selectin concentration at baseline (ratio to baseline).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers at baseline and at the specified time point. At Cycle 4, Day 28, median and/or standard deviation were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.222"}]}]},{"title":"Cycle 2, Day 1 (n=29)","categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.287"}]}]},{"title":"Cycle 2, Day 28 (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.246"}]}]},{"title":"Cycle 3, Day 1 (n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.224"}]}]},{"title":"Cycle 3, Day 28 (n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"0.126"}]}]},{"title":"Cycle 5, Day 28 (n=3)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.354"}]}]}]},{"type":"SECONDARY","title":"VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of VEGFR3 at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers and tumor response at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"pg/mL","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Cycle 1, Day 1 (CR or PR or SD, n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"21660.00"}]}]},{"title":"Cycle 1, Day 1 (PD, n=24)","categories":[{"measurements":[{"groupId":"OG000","value":"27740.00"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.474","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median VEGFR3 concentration at each time point divided by median VEGFR3 concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers at baseline and at the specified time point. No subjects had PD at Cycle 5, Day 28.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"classes":[{"title":"Cycle 1, Day 28 (CR or PR or SD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.34"}]}]},{"title":"Cycle 1, Day 28 (PD, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"0.35"}]}]},{"title":"Cycle 2, Day 1 (CR or PR or SD, n=19)","categories":[{"measurements":[{"groupId":"OG000","value":"0.75"}]}]},{"title":"Cycle 2, Day 1 (PD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.84"}]}]},{"title":"Cycle 2, Day 28 (CR or PR or SD, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"0.32"}]}]},{"title":"Cycle 2, Day 28 (PD, n=12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.38"}]}]},{"title":"Cycle 3, Day 1 (CR or PR or SD, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"0.57"}]}]},{"title":"Cycle 3, Day 1 (PD, n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.92"}]}]},{"title":"Cycle 3, Day 28 (CR or PR or SD, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"0.38"}]}]},{"title":"Cycle 3, Day 28 (pd, n=1)","categories":[{"measurements":[{"groupId":"OG000","value":"0.43"}]}]},{"title":"Cycle 5, Day 28 (CR or PR or SD, n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"0.30"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.836","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.071","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.393","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.029","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.247","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of VEGF-C at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers and tumor response at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"pg/mL","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"classes":[{"title":"Cycle 1, Day 1 (CR or PR or SD, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"704.80"}]}]},{"title":"Cycle 1, Day 1 (PD, n=24)","categories":[{"measurements":[{"groupId":"OG000","value":"766.45"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.305","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median VEGF-C concentration at each time point divided by median VEGF-C concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. No subjects had PD at Cycle 5, Day 28.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"classes":[{"title":"Cycle 1, Day 28 (CR or PR or SD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.73"}]}]},{"title":"Cycle 1, Day 28 (PD, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81"}]}]},{"title":"Cycle 2, Day 1 (CR or PR or SD, n=18)","categories":[{"measurements":[{"groupId":"OG000","value":"0.87"}]}]},{"title":"Cycle 2, Day 1 (PD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.85"}]}]},{"title":"Cycle 2, Day 28 (CR or PR or SD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.89"}]}]},{"title":"Cycle 2, Day 28 (PD, n=12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.69"}]}]},{"title":"Cycle 3, Day 1 (CR or PR or SD, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.89"}]}]},{"title":"Cycle 3, Day 1 (PD, n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78"}]}]},{"title":"Cycle 3, Day 28 (CR or PR or SD, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"0.85"}]}]},{"title":"Cycle 3, Day 28 (PD, n=1)","categories":[{"measurements":[{"groupId":"OG000","value":"0.90"}]}]},{"title":"Cycle 5, Day 28 (CR or PR or SD, n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.738","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.438","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.236","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.287","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.772","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median concentration of soluble E-selectin at baseline stratified by tumor response (CR or PR or \\[SD \\> = 6 Weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a nonparametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with levels of soluble protein biomarkers and tumor response at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"pg/mL","timeFrame":"Baseline (Cycle 1, Day 1) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"classes":[{"title":"Cycle 1, Day 1 (CR or PR or SD, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"26.40"}]}]},{"title":"Cycle 1, Day 1 (PD, n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"27.40"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.537","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)","description":"Median soluble E-selectin concentration at each time point divided by median soluble E-selectin concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or \\[SD \\> = 6 weeks\\] or PD). A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. No subjects had PD at Cycle 4, Day 28 and Cycle 5, Day 28.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"ratio","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"classes":[{"title":"Cycle 1, Day 28 (CR or PR or SD, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.84"}]}]},{"title":"Cycle 1, Day 28 (PD, n=16)","categories":[{"measurements":[{"groupId":"OG000","value":"0.84"}]}]},{"title":"Cycle 2, Day 1 (CR or PR or SD, n=13)","categories":[{"measurements":[{"groupId":"OG000","value":"0.84"}]}]},{"title":"Cycle 2, Day 1 (PD, n=12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76"}]}]},{"title":"Cycle 2, Day 28 (CR or PR or SD, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.86"}]}]},{"title":"Cycle 2, Day 28 (PD, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.64"}]}]},{"title":"Cycle 3, Day 1 (CR or PR or SD, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.74"}]}]},{"title":"Cycle 3, Day 1 (PD, n=5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77"}]}]},{"title":"Cycle 3, Day 28 (CR or PR or SD, n=7)","categories":[{"measurements":[{"groupId":"OG000","value":"0.67"}]}]},{"title":"Cycle 3, Day 28 (PD, n=1)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78"}]}]},{"title":"Cycle 4, Day 28 (CR or PR or SD, n=1)","categories":[{"measurements":[{"groupId":"OG000","value":"1.13"}]}]},{"title":"Cycle 5, Day 28 (CR or PR or SD, n=3)","categories":[{"measurements":[{"groupId":"OG000","value":"0.64"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.813","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.849","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.121","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.582","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.383","statisticalMethod":"Wilcoxon Rank Sum Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1)divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after Stratification by \\< or \\> = median changes from Baseline in VEGFR3 at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 28 (\\< median cutpoint) and Cycle 5, Day 28 (\\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"10.11","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.12","upperLimit":"16.10"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"9.97","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"6.84","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"15.81","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"10.83","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"10.83","upperLimit":"32.91"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"22.51","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"9.97","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"21.79","upperLimit":"45.73"}]}]},{"title":"Cycle 5, Day 28 (< Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"38.3","lowerLimit":"30.77","upperLimit":"45.87"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6782","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.61","ciUpperLimit":"2.15","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1980","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"3.30","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1344","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"3.98","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4809","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"3.39","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0153","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"3.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.19","ciUpperLimit":"11.13","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group"},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2085","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"2.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"14.37","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group"},{"groupIds":["OG000"],"groupDescription":"Cycle 5, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8084","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.08","ciUpperLimit":"23.57","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group"}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 28 (\\< median cutpoint) and Cycle 5, Day 28 (\\< median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=29)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"8.97","upperLimit":"15.81"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"8.97","upperLimit":"43.30"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.97","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=19)","categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"10.11","upperLimit":"22.51"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"10.11","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"31.8","lowerLimit":"16.10","upperLimit":"45.73"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"10.11","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"15.81","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"30.77","upperLimit":"45.73"}]}]},{"title":"Cycle 5, Day 28 (> = Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"37.0","lowerLimit":"30.77","upperLimit":"43.30"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5070","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.65","ciUpperLimit":"2.39","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4474","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"2.82","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7599","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"1.95","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0109","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.12","ciUpperLimit":"0.80","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6878","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.43","ciUpperLimit":"3.58","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4637","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"8.12","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline","description":"PFS = time from start of study treatment to first documentation of objective disease progression or to death on study due to any cause, whichever was first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 2, Day 28 (\\> = median cutpoint), Cycle 3, Day 28 (\\< median cutpoint), and Cycles 4 and 5, Day 28 (\\< median cutpoint, \\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"[Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=26)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"9.12","upperLimit":"22.51"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.97","upperLimit":"21.79"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.26","upperLimit":"21.79"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"6.84","upperLimit":"16.10"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"10.11","upperLimit":"45.87"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.11","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"10.11","upperLimit":"16.81"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"9.97","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"10.11","upperLimit":"43.30"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"43.3","lowerLimit":"16.10","upperLimit":"43.30"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5277","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"1.62","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4660","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.58","ciUpperLimit":"3.29","estimateComment":"HR was based upon the ratio of \\>=Median Cutpoint group hazard to \\<Median Cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5337","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"3.44","estimateComment":"HR was based upon the ratio of \\>=Median Cutpoint group hazard to \\<Median Cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0712","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.13","ciUpperLimit":"1.13","estimateComment":"HR was based upon the ratio of \\>=Median Cutpoint group hazard to \\<Median Cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2948","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"2.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"7.07","estimateComment":"HR was based upon the ratio of \\>=Median Cutpoint group hazard to \\<Median Cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3200","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"3.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"38.48","estimateComment":"HR was based upon the ratio of \\>=Median Cutpoint group hazard to \\<Median Cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after stratification by \\< or \\> = median changes from baseline in VEGFR3 at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 28 (\\< median cutpoint) and Cycle 5, Day 28 (\\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"10.83","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.26","upperLimit":"21.79"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"9.97","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"9.97","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"15.81","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"10.83","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"10.83","upperLimit":"32.91"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"30.77","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"9.97","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"21.79","upperLimit":"45.73"}]}]},{"title":"Cycle 5, Day 28 (< Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"38.3","lowerLimit":"30.77","upperLimit":"45.87"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7824","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"2.17","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1918","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"3.47","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1093","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"4.30","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4809","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"3.39","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0110","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"4.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.26","ciUpperLimit":"13.85","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2085","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"2.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"14.37","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 5, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8084","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.08","ciUpperLimit":"23.57","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 28 (\\< median cutpoint), and Cycle 5, Day 28 (\\< median cutpoint, \\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=29)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"32.91"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.26","upperLimit":"16.81"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"9.12","upperLimit":"43.30"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.97","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=19)","categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"10.11","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.97","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"10.11","upperLimit":"16.81"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"31.8","lowerLimit":"16.10","upperLimit":"45.73"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"10.11","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"15.81","upperLimit":"33.90"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"30.77","upperLimit":"45.73"}]}]},{"title":"Cycle 5, Day 28 (> = Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"37.0","lowerLimit":"30.77","upperLimit":"43.30"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5215","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"2.53","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2504","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"3.49","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8766","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.42","ciUpperLimit":"2.11","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0109","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.12","ciUpperLimit":"0.80","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5627","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"4.18","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4637","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"8.12","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline","description":"TTP = time from start of study treatment to first documentation of objective disease progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first sunitinib dose date +1) divided by 7.02. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 2, Day 28 (\\> = median cutpoint), Cycle 3, Day 28 (\\< median cutpoint), and Cycles 4 and 5, Day 28 (\\< median cutpoint, \\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=26)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"9.97","upperLimit":"43.30"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"10.11","upperLimit":"33.90"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.26","upperLimit":"21.79"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"9.12","upperLimit":"43.30"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"10.11","upperLimit":"45.87"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"10.11","upperLimit":"33.90"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"10.11","upperLimit":"16.81"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"9.97","upperLimit":"45.87"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"33.9","lowerLimit":"10.11","upperLimit":"43.30"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"43.3","lowerLimit":"16.10","upperLimit":"43.30"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6682","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"1.84","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6854","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"3.00","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6028","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"3.37","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0712","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.13","ciUpperLimit":"1.13","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3411","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.50","ciUpperLimit":"7.15","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3200","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"3.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"38.48","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline","description":"OS = time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death minus date of sunitinib first dose +1)divided by 30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of VEGFR3 at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGFR3 at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 1 (\\< median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"6.55","upperLimit":"20.53"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"4.51","upperLimit":"9.67"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"5.23","upperLimit":"22.89"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.41","upperLimit":"11.15"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"13.7","lowerLimit":"6.12","upperLimit":"22.89"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"6.55","upperLimit":"24.47"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"7.11","upperLimit":"22.89"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"8.82","upperLimit":"26.09"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.07","upperLimit":"13.26"}]}]},{"title":"Cycle 3, Day 28 (< Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"17.7","lowerLimit":"13.65","upperLimit":"22.89"}]}]},{"title":"Cycle 5, Day 28 (< Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"13.65","upperLimit":"20.53"}]}]},{"title":"Cycle 5, Day 28 (> = Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"12.66","upperLimit":"14.84"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4768","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"2.17","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1484","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"3.13","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8957","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.50","ciUpperLimit":"2.18","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5681","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.33","ciUpperLimit":"1.85","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0074","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"3.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.35","ciUpperLimit":"10.88","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1637","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"1.70","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 5, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4328","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"2.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.23","ciUpperLimit":"29.12","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline","description":"OS = time from start of study treatment to death due to any cause. OS (in months) was calculated as (date of death minus date of sunitinib first dose +1) divided by 30.4. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of VEGF-C at Baseline and after stratification by \\< or \\> = median changes from Baseline in VEGF-C at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 28 (\\> = median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=29)","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"6.32","upperLimit":"15.76"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=30)","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"4.41","upperLimit":"12.66"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"5.07","upperLimit":"14.84"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=23)","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"4.41","upperLimit":"20.53"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=19)","categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"5.20","upperLimit":"14.84"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"6.55","upperLimit":"22.89"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"4.41","upperLimit":"24.47"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"13.26","upperLimit":"22.89"}]}]},{"title":"Cycle 3, Day 1 (< Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"5.20","upperLimit":"14.84"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"13.26","upperLimit":"22.89"}]}]},{"title":"Cycle 3, Day 28 (< Median Cutpoint, n=6)","categories":[{"measurements":[{"groupId":"OG000","value":"14.2","lowerLimit":"12.66","upperLimit":"14.84"}]}]},{"title":"Cycle 5, Day 28 (< Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"14.2","lowerLimit":"13.65","upperLimit":"14.84"}]}]},{"title":"Cycle 5, Day 28 (> = Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"12.66","upperLimit":"20.53"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4269","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"2.21","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9290","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"1.86","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8195","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.44","ciUpperLimit":"1.91","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2210","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.26","ciUpperLimit":"1.38","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4297","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"1.85","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0522","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"1.11","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 5, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6949","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.05","ciUpperLimit":"7.00","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline","description":"OS=time from start of study treatment to death due to any cause. OS (in months) calculated as (date of death minus date of sunitinib first dose +1) divided by 30.4. For subjects not expiring their survival times were censored at last date of known contact they were known to be alive. Subjects lacking data beyond day of first dose of sunitinib had their survival time censored at Day 1 of sunitinib treatment. Groups are defined by \\< or \\> = median levels of soluble E-selectin at Baseline and after stratification by \\< or \\> = median changes from Baseline in soluble E-selectin at each time point.","populationDescription":"MITT. n=number of subjects with soluble protein biomarkers at baseline and at the specified time point. At Cycle 3, Day 1 (\\< median cutpoint), Cycle 4, Day 28 (\\< median cutpoint, \\> = median cutpoint)and Cycle 5, Day 28 (\\< median cutpoint), median and/or CI were not able to be estimated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Cycle 1 (Day 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28), Cycle 4 (Day 28), Cycle 5 (Day 28) of Part 2","groups":[{"id":"OG000","title":"Sunitinib","description":"Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"classes":[{"title":"Cycle 1, Day 1 (< Median Cutpoint, n=26)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"4.24","upperLimit":"12.66"}]}]},{"title":"Cycle 1, Day 1 (> = Median Cutpoint, n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"4.51","upperLimit":"13.65"}]}]},{"title":"Cycle 1, Day 28 (< Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"4.57","upperLimit":"24.47"}]}]},{"title":"Cycle 1, Day 28 (> = Median Cutpoint, n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"3.95","upperLimit":"14.84"}]}]},{"title":"Cycle 2, Day 1 (< Median Cutpoint, n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"4.51","upperLimit":"24.47"}]}]},{"title":"Cycle 2, Day 1 (> = Median Cutpoint, n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"5.23","upperLimit":"13.26"}]}]},{"title":"Cycle 2, Day 28 (< Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"4.41","upperLimit":"24.47"}]}]},{"title":"Cycle 2, Day 28 (> = Median Cutpoint, n=11)","categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"12.66","upperLimit":"22.89"}]}]},{"title":"Cycle 3, Day 1 (> = Median Cutpoint, n=8)","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"5.07","upperLimit":"14.84"}]}]},{"title":"Cycle 3, Day 28 (> = Median Cutpoint, n=4)","categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"12.66","upperLimit":"22.89"}]}]},{"title":"Cycle 5, Day 28 (> = Median Cutpoint, n=2)","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"12.66","upperLimit":"14.84"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7660","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"1.65","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 1, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2682","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"3.23","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2726","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.69","ciUpperLimit":"3.70","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 2, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2787","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.22","ciUpperLimit":"1.55","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 1","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0241","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.09","ciUpperLimit":"17.56","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 3, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0943","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"5.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"48.81","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."},{"groupIds":["OG000"],"groupDescription":"Cycle 5, Day 28","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8084","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.04","ciUpperLimit":"11.79","estimateComment":"HR was based upon the ratio of \\> = median cutpoint group hazard to \\< median cutpoint group."}]},{"type":"SECONDARY","title":"Immunohistochemical Staining of Paraffin Embedded Tumor Tissue","description":"Previously collected tumor paraffin block (or 12-20 10-micron slides prepared for the paraffin block) for correlative laboratory analysis.","populationDescription":"Samples were collected and stained from a subset of subjects. Due to the small sample size, no correlative analyses with clinical outcome were conducted.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"samples","timeFrame":"Screening","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms to Safety of Sunitinib","description":"A blood sample (6 mL) was collected and used to isolate DNA. These samples were not anonymized.","populationDescription":"c-Kit, Flt-3 and c-Fms to safety of Sunitinib samples were collected and analyzed. However, there was no statistics performed since power was insufficient.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"pg/mL","timeFrame":"Within 7 days of Day 1","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)","description":"EORTC QLQ-C30 scales: global health/QoL, functional domains (physical, role, cognitive, emotional, social), and symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea). Recall period: past week; response range: not at all to very much, global/QOL range: very poor to excellent. Scale score range: 0 to 100. Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms. Change: score at each visit in Part 2 minus baseline score in Part 1.","populationDescription":"ITT. Number of participants analyzed = number of subjects with EORTC response (defined as having at least 1 item response on the EORTC). n=number of subjects with EORTC scale score at baseline and each specified time point. Data in cycles with less than 9 subjects are not reported due to lack of statistical reliability.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline (Part 1) to Cycle1 (Days 1 [baseline], 28), Cycles 2 and 3 (Days 1, 28), and Cycle 4 (Day 1) in Part 2","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"title":"Cycle 1, Day 1 Global Health Status /QoL (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"3.580"}]}]},{"title":"Cycle 1, Day 28 Global Health Status /QoL (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.13","spread":"3.964"}]}]},{"title":"Cycle 2, Day 1 Global Health Status /QoL (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":"3.361"}]}]},{"title":"Cycle 2, Day 28 Global Health Status /QoL (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.13","spread":"4.704"}]}]},{"title":"Cycle 3, Day 1 Global Health Status /QoL (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"7.175"}]}]},{"title":"Cycle 3, Day 28 Global Health Status /QoL (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"8.056"}]}]},{"title":"Cycle 4, Day 1 Global Health Status /QoL (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"4.883"}]}]},{"title":"Cycle 1, Day 1 Physical Functioning (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.79","spread":"2.806"}]}]},{"title":"Cycle 1, Day 28 Physical Functioning (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.68","spread":"2.363"}]}]},{"title":"Cycle 2, Day 1 Physical Functioning (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.43","spread":"2.941"}]}]},{"title":"Cycle 2, Day 28 Physical Functioning (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"-12.42","spread":"4.771"}]}]},{"title":"Cycle 3, Day 1 Physical Functioning (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.78","spread":"3.178"}]}]},{"title":"Cycle 3, Day 28 Physical Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.33","spread":"7.647"}]}]},{"title":"Cycle 4, Day 1 Physical Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"5.072"}]}]},{"title":"Cycle 1, Day 1 Role Functioning (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-16.05","spread":"4.641"}]}]},{"title":"Cycle 1, Day 28 Role Functioning (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-20.63","spread":"5.383"}]}]},{"title":"Cycle 2, Day 1 Role Functioning (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-13.81","spread":"4.950"}]}]},{"title":"Cycle 2, Day 28 Role Functioning (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"-28.03","spread":"8.234"}]}]},{"title":"Cycle 3, Day 1 Role Functioning (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"7.968"}]}]},{"title":"Cycle 3, Day 28 Role Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-15.00","spread":"13.017"}]}]},{"title":"Cycle 4, Day 1 Role Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"11.180"}]}]},{"title":"Cycle 1, Day 1 Emotional Functioning (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.16","spread":"3.512"}]}]},{"title":"Cycle 1, Day 28 Emotional Functioning (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"3.139"}]}]},{"title":"Cycle 2, Day 1 Emotional Functioning (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"3.649"}]}]},{"title":"Cycle 2, Day 28 Emotional Functioning (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"4.668"}]}]},{"title":"Cycle 3, Day 1 Emotional Functioning (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"13.10","spread":"3.571"}]}]},{"title":"Cycle 3, Day 28 Emotional Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"4.348"}]}]},{"title":"Cycle 4, Day 1 Emotional Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"24.17","spread":"5.038"}]}]},{"title":"Cycle 1, Day 1 Cognitive Functioning (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.95","spread":"3.138"}]}]},{"title":"Cycle 1, Day 28 Cognitive Functioning (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.57","spread":"3.704"}]}]},{"title":"Cycle 2, Day 1 Cognitive Functioning (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.00","spread":"3.817"}]}]},{"title":"Cycle 2, Day 28 Cognitive Functioning (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.32","spread":"5.573"}]}]},{"title":"Cycle 3, Day 1 Cognitive Functioning (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"3.692"}]}]},{"title":"Cycle 3, Day 28 Cognitive Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"4.615"}]}]},{"title":"Cycle 4, Day 1 Cognitive Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":"5.000"}]}]},{"title":"Cycle 1, Day 1 Social Functioning (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.64","spread":"4.250"}]}]},{"title":"Cycle 1, Day 28 Social Functioning (n=41)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.98","spread":"5.417"}]}]},{"title":"Cycle 2, Day 1 Social Functioning (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.31","spread":"5.228"}]}]},{"title":"Cycle 2, Day 28 Social Functioning (n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"-25.00","spread":"7.204"}]}]},{"title":"Cycle 3, Day 1 Social Functioning (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.14","spread":"5.980"}]}]},{"title":"Cycle 3, Day 28 Social Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.453"}]}]},{"title":"Cycle 4, Day 1 Social Functioning (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"7.222"}]}]},{"title":"Cycle 1, Day 1 Fatigue (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"13.48","spread":"3.411"}]}]},{"title":"Cycle 1, Day 28 Fatigue (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"16.40","spread":"3.921"}]}]},{"title":"Cycle 2, Day 1 Fatigue (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":"4.083"}]}]},{"title":"Cycle 2, Day 28 Fatigue (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"19.70","spread":"6.025"}]}]},{"title":"Cycle 3, Day 1 Fatigue (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"6.548"}]}]},{"title":"Cycle 3, Day 28 Fatigue (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"11.355"}]}]},{"title":"Cycle 4, Day 1 Fatigue (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"7.490"}]}]},{"title":"Cycle 1, Day 1 Nausea and Vomiting (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"2.988"}]}]},{"title":"Cycle 1, Day 28 Nausea and Vomiting (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"11.90","spread":"3.822"}]}]},{"title":"Cycle 2, Day 1 Nausea and Vomiting (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"4.491"}]}]},{"title":"Cycle 2, Day 28 Nausea and Vomiting (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"6.82","spread":"4.608"}]}]},{"title":"Cycle 3, Day 1 Nausea and Vomiting (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"5.789"}]}]},{"title":"Cycle 3, Day 28 Nausea and Vomiting (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"11.67","spread":"7.049"}]}]},{"title":"Cycle 4, Day 1 Nausea and Vomiting (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"6.310"}]}]},{"title":"Cycle 1, Day 1 Pain (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":"4.228"}]}]},{"title":"Cycle 1, Day 28 Pain (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"3.766"}]}]},{"title":"Cycle 2, Day 1 Pain (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"5.24","spread":"4.572"}]}]},{"title":"Cycle 2, Day 28 Pain (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"5.748"}]}]},{"title":"Cycle 3, Day 1 Pain (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"6.640"}]}]},{"title":"Cycle 3, Day 28 Pain (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"8.767"}]}]},{"title":"Cycle 4, Day 1 Pain (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"7.778"}]}]},{"title":"Cycle 1, Day 1 Dyspnea (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"3.396"}]}]},{"title":"Cycle 1, Day 28 Dyspnea (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"3.760"}]}]},{"title":"Cycle 2, Day 1 Dyspnea (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"4.352"}]}]},{"title":"Cycle 2, Day 28 Dyspnea (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"-13.64","spread":"6.454"}]}]},{"title":"Cycle 3, Day 1 Dyspnea (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.89","spread":"3.940"}]}]},{"title":"Cycle 3, Day 28 Dyspnea (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"8.607"}]}]},{"title":"Cycle 4, Day 1 Dyspnea (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-13.33","spread":"7.370"}]}]},{"title":"Cycle 1, Day 1 Insomnia (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"5.006"}]}]},{"title":"Cycle 1, Day 28 Insomnia (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"5.671"}]}]},{"title":"Cycle 2, Day 1 Insomnia (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"5.529"}]}]},{"title":"Cycle 2, Day 28 Insomnia (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"6.06","spread":"8.672"}]}]},{"title":"Cycle 3, Day 1 Insomnia (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"6.057"}]}]},{"title":"Cycle 3, Day 28 Insomnia (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"10.887"}]}]},{"title":"Cycle 4, Day 1 Insomnia (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-20.00","spread":"7.370"}]}]},{"title":"Cycle 1, Day 1 Appetite Loss (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"5.138"}]}]},{"title":"Cycle 1, Day 28 Appetite Loss (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"20.63","spread":"5.898"}]}]},{"title":"Cycle 2, Day 1 Appetite Loss (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"7.633"}]}]},{"title":"Cycle 2, Day 28 Appetite Loss (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"10.61","spread":"7.068"}]}]},{"title":"Cycle 3, Day 1 Appetite Loss (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"7.606"}]}]},{"title":"Cycle 3, Day 28 Appetite Loss (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"12.373"}]}]},{"title":"Cycle 4, Day 1 Appetite Loss (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"10.887"}]}]},{"title":"Cycle 1, Day 1 Constipation (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"4.109"}]}]},{"title":"Cycle 1, Day 28 Constipation (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"5.266"}]}]},{"title":"Cycle 2, Day 1 Constipation (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"4.965"}]}]},{"title":"Cycle 2, Day 28 Constipation (n=22)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"6.317"}]}]},{"title":"Cycle 3, Day 1 Constipation (n=15)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.44","spread":"6.397"}]}]},{"title":"Cycle 3, Day 28 Constipation (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"6.667"}]}]},{"title":"Cycle 4, Day 1 Constipation (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.00","spread":"5.092"}]}]},{"title":"Cycle 1, Day 1 Diarrhea (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"2.206"}]}]},{"title":"Cycle 1, Day 28 Diarrhea (n=41)","categories":[{"measurements":[{"groupId":"OG000","value":"13.01","spread":"5.058"}]}]},{"title":"Cycle 2, Day 1 Diarrhea (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"11.43","spread":"4.916"}]}]},{"title":"Cycle 2, Day 28 Diarrhea (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":"5.589"}]}]},{"title":"Cycle 3, Day 1 Diarrhea (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"6.767"}]}]},{"title":"Cycle 3, Day 28 Diarrhea (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"26.67","spread":"9.686"}]}]},{"title":"Cycle 4, Day 1 Diarrhea (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"9.938"}]}]},{"title":"Cycle 1, Day 1 Financial Difficulties (n=54)","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"2.607"}]}]},{"title":"Cycle 1, Day 28 Financial Difficulties (n=42)","categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"2.381"}]}]},{"title":"Cycle 2, Day 1 Financial Difficulties (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"5.88","spread":"4.331"}]}]},{"title":"Cycle 2, Day 28 Financial Difficulties (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"6.35","spread":"5.453"}]}]},{"title":"Cycle 3, Day 1 Financial Difficulties (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.90","spread":"7.500"}]}]},{"title":"Cycle 3, Day 28 Financial Difficulties (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"10.184"}]}]},{"title":"Cycle 4, Day 1 Financial Difficulties (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"10.184"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13)","description":"QLQ-LC13 assessed lung cancer symptoms (dyspnea, coughing, dysphasia, hemoptysis, sore mouth, peripheral neuropathy, alopecia, chest pain, arm pain, shoulder pain, and pain in other parts). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms. Change: score at each visit in Part 2 minus baseline score in Part 1.","populationDescription":"ITT. Number of participants analyzed = number of subjects with EORTC response (defined as having at least 1 item response on the EORTC). n=number of subjects with EORTC scale score at baseline and each specified time point. Data in cycles with less than 9 subjects are not reported due to lack of statistical reliability.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline (Part 1) to Cycle1 (Days 1 [baseline], 28), Cycles 2 and 3 (Days 1, 28), and Cycle 4 (Day 1) in Part 2","groups":[{"id":"OG000","title":"First Carboplatin Plus Paclitaxel, Then Sunitinib","description":"Part 1 = Carboplatin plus Paclitaxel 172-225 mg/m2. Part 2 = Sunitinib 50 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"title":"Cycle 1, Day 1 Dyspnea (n=49)","categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"3.008"}]}]},{"title":"Cycle 1, Day 28 Dyspnea (n=37)","categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"3.030"}]}]},{"title":"Cycle 2, Day 1 Dyspnea (n=31)","categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":"4.112"}]}]},{"title":"Cycle 2, Day 28 Dyspnea (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"4.490"}]}]},{"title":"Cycle 3, Day 1 Dyspnea (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"3.466"}]}]},{"title":"Cycle 3, Day 28 Dyspnea (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"4.94","spread":"6.705"}]}]},{"title":"Cycle 4, Day 1 Dyspnea (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"3.208"}]}]},{"title":"Cycle 1, Day 1 Coughing (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"-14.47","spread":"5.120"}]}]},{"title":"Cycle 1, Day 28 Coughing (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"-14.17","spread":"5.048"}]}]},{"title":"Cycle 2, Day 1 Coughing (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"-12.75","spread":"5.077"}]}]},{"title":"Cycle 2, Day 28 Coughing (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"-15.87","spread":"7.496"}]}]},{"title":"Cycle 3, Day 1 Coughing (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.52","spread":"5.445"}]}]},{"title":"Cycle 3, Day 28 Coughing (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-13.33","spread":"7.370"}]}]},{"title":"Cycle 4, Day 1 Coughing (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"7.857"}]}]},{"title":"Cycle 1, Day 1 Hemoptysis (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"1.678"}]}]},{"title":"Cycle 1, Day 28 Hemoptysis (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":"3.362"}]}]},{"title":"Cycle 2, Day 1 Hemoptysis (n=33)","categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"1.406"}]}]},{"title":"Cycle 2, Day 28 Hemoptysis (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"2.795"}]}]},{"title":"Cycle 3, Day 1 Hemoptysis (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.38","spread":"2.381"}]}]},{"title":"Cycle 3, Day 28 Hemoptysis (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"Cycle 4, Day 1 Hemoptysis (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.70","spread":"3.704"}]}]},{"title":"Cycle 1, Day 1 Sore Mouth (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.66","spread":"3.782"}]}]},{"title":"Cycle 1, Day 28 Sore Mouth (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"7.141"}]}]},{"title":"Cycle 2, Day 1 Sore Mouth (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"9.80","spread":"7.111"}]}]},{"title":"Cycle 2, Day 28 Sore Mouth (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"12.70","spread":"6.289"}]}]},{"title":"Cycle 3, Day 1 Sore Mouth (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"3.494"}]}]},{"title":"Cycle 3, Day 28 Sore Mouth (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"13.194"}]}]},{"title":"Cycle 4, Day 1 Sore Mouth (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"7.857"}]}]},{"title":"Cycle 1, Day 1 Dysphasia (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"3.298"}]}]},{"title":"Cycle 1, Day 28 Dysphasia (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"4.697"}]}]},{"title":"Cycle 2, Day 1 Dysphasia (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"5.145"}]}]},{"title":"Cycle 2, Day 28 Dysphasia (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"2.795"}]}]},{"title":"Cycle 3, Day 1 Dysphasia (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"4.762"}]}]},{"title":"Cycle 3, Day 28 Dysphasia (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.00","spread":"5.092"}]}]},{"title":"Cycle 4, Day 1 Dysphasia (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"5.556"}]}]},{"title":"Cycle 1, Day 1 Peripheral Neuropathy (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"42.14","spread":"5.012"}]}]},{"title":"Cycle 1, Day 28 Peripheral Neuropathy (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"32.50","spread":"5.402"}]}]},{"title":"Cycle 2, Day 1 Peripheral Neuropathy (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"28.43","spread":"5.825"}]}]},{"title":"Cycle 2, Day 28 Peripheral Neuropathy (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"26.98","spread":"7.841"}]}]},{"title":"Cycle 3, Day 1 Peripheral Neuropathy (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"23.81","spread":"10.145"}]}]},{"title":"Cycle 3, Day 28 Peripheral Neuropathy (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"10.184"}]}]},{"title":"Cycle 4, Day 1 Peripheral Neuropathy (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"7.407"}]}]},{"title":"Cycle 1, Day 1 Alopecia (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"63.52","spread":"5.407"}]}]},{"title":"Cycle 1, Day 28 Alopecia (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"40.83","spread":"7.009"}]}]},{"title":"Cycle 2, Day 1 Alopecia (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"30.39","spread":"7.627"}]}]},{"title":"Cycle 2, Day 28 Alopecia (n=20)","categories":[{"measurements":[{"groupId":"OG000","value":"11.67","spread":"7.752"}]}]},{"title":"Cycle 3, Day 1 Alopecia (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"Cycle 3, Day 28 Alopecia (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"Cycle 4, Day 1 Alopecia (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"Cycle 1, Day 1 Pain in Chest (n=53)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.18","spread":"3.581"}]}]},{"title":"Cycle 1, Day 28 Pain in Chest (n=40)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"3.415"}]}]},{"title":"Cycle 2, Day 1 Pain in Chest (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"3.850"}]}]},{"title":"Cycle 2, Day 28 Pain in Chest (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"3.984"}]}]},{"title":"Cycle 3, Day 1 Pain in Chest (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"5.906"}]}]},{"title":"Cycle 3, Day 28 Pain in Chest (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"7.027"}]}]},{"title":"Cycle 4, Day 1 Pain in Chest (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"9.259"}]}]},{"title":"Cycle 1, Day 1 Pain in Arm or Shoulder (n=51)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"4.171"}]}]},{"title":"Cycle 1, Day 28 Pain in Arm or Shoulder (n=39)","categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"4.497"}]}]},{"title":"Cycle 2, Day 1 Pain in Arm or Shoulder (n=34)","categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":"6.257"}]}]},{"title":"Cycle 2, Day 28 Pain in Arm or Shoulder (n=21)","categories":[{"measurements":[{"groupId":"OG000","value":"3.17","spread":"4.545"}]}]},{"title":"Cycle 3, Day 1 Pain in Arm or Shoulder (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"4.228"}]}]},{"title":"Cycle 3, Day 28 Pain in Arm or Shoulder (n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"11.967"}]}]},{"title":"Cycle 4, Day 1 Pain in Arm or Shoulder (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"11.111"}]}]},{"title":"Cycle 1, Day 1 Pain in Other Parts (n=47)","categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":"6.431"}]}]},{"title":"Cycle 1, Day 28 Pain in Other Parts (n=35)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"5.925"}]}]},{"title":"Cycle 2, Day 1 Pain in Other Parts (n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"12.35","spread":"7.368"}]}]},{"title":"Cycle 2, Day 28 Pain in Other Parts (n=17)","categories":[{"measurements":[{"groupId":"OG000","value":"13.73","spread":"8.603"}]}]},{"title":"Cycle 3, Day 1 Pain in Other Parts (n=14)","categories":[{"measurements":[{"groupId":"OG000","value":"11.90","spread":"8.274"}]}]},{"title":"Cycle 3, Day 28 Pain in Other Parts (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"9.623"}]}]},{"title":"Cycle 4, Day 1 Pain in Other Parts (n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"9.623"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Part 1 = adverse events (AEs) reported occurred during chemotherapy treatment. Part 2 = AEs reported occurred on or after the first dose of sunitinib.","eventGroups":[{"id":"EG000","title":"Carboplatin Plus Paclitaxel 172-225 mg/m2 (Part 1)","seriousNumAffected":29,"seriousNumAtRisk":84,"otherNumAffected":82,"otherNumAtRisk":84},{"id":"EG001","title":"Sunitinib 50 mg (Part 2)","seriousNumAffected":29,"seriousNumAtRisk":66,"otherNumAffected":60,"otherNumAtRisk":66}],"seriousEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":3,"numAtRisk":66}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":3,"numAtRisk":66}]},{"term":"Haemorrhage urinary tract","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Hypercapnia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Tachypnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Coagulation time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Cerebellar syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Phlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":1,"numAtRisk":66}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":84},{"groupId":"EG001","numAffected":12,"numAtRisk":66}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":84},{"groupId":"EG001","numAffected":13,"numAtRisk":66}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":24,"numAtRisk":66}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":84},{"groupId":"EG001","numAffected":21,"numAtRisk":66}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":84},{"groupId":"EG001","numAffected":12,"numAtRisk":66}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":84},{"groupId":"EG001","numAffected":17,"numAtRisk":66}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":84},{"groupId":"EG001","numAffected":21,"numAtRisk":66}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":8,"numAtRisk":66}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":84},{"groupId":"EG001","numAffected":16,"numAtRisk":66}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":84},{"groupId":"EG001","numAffected":5,"numAtRisk":66}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":84},{"groupId":"EG001","numAffected":10,"numAtRisk":66}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":84},{"groupId":"EG001","numAffected":2,"numAtRisk":66}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":84},{"groupId":"EG001","numAffected":12,"numAtRisk":66}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":84},{"groupId":"EG001","numAffected":0,"numAtRisk":66}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":6,"numAtRisk":66}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":5,"numAtRisk":66}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":7,"numAtRisk":66}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":4,"numAtRisk":66}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":84},{"groupId":"EG001","numAffected":9,"numAtRisk":66}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of \\< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \\< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.govCallCenter@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000077210","term":"Sunitinib"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":true}